Healthcare Industry News:  cell therapy 

Regenerative Medicine

 News Release - February 2, 2010

Bio-Matrix Scientific Group's Majority Owned Subsidiary Entest BioMedical Initiates Studies to Support Stem Cell / Laser Regenerative Therapy for COPD

Every 4 Minutes an American Dies of COPD

24 Million Americans Have COPD and 12 Million Don't Know It

$170 Billion over the Next 5 Years Will Be Spent Treating COPD

SAN DIEGO, CA - (HSMN NewsFeed) - Bio-Matrix Scientific Group Inc. (OTC.BB:BMSN ) announced that its majority owned subsidiary, Entest BioMedical Inc. (OTC.BB:ENTB ) has initiated studies to support the Company's stem cell / laser regenerative therapy for Chronic Obstructive Pulmonary Disease (COPD).

According to a Company spokesperson, Entest has begun to research the effects of Low Energy Near Infrared Radiation on cultured cells as a step toward animal pre-clinical studies for the treatment of COPD. Studies will be an extension of current Entest intellectual property covering enhancement of stem cell growth and activity. Specific focus will be placed on type II alveolar epithelial cells and related stem cells known to reside in the lung.

Dr. Steve Josephs, Co-Principal Investigator for Entest, states, "We are pleased with the progress of our ENT-576 program which uses Low Level Laser (LLL) therapy for COPD as a means of inhibiting inflammation and stimulating lung regeneration. We view these studies as critical in determining the direction of our pre-clinical and clinical research."

Entest's Chairman & CEO David Koos, stated, "According to the COPD Foundation, every 4 minutes an American dies of COPD. It is estimated there are over 24 million cases of COPD in the US, of which 12 million people don't even know they have it. Our research represents hope for the future in curing COPD."

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTC.BB:ENTB ) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT-576 is a proprietary laser device currently under development by Entest. The Company has filed 3 patent applications relating to the treatment of COPD.

About Bio-Matrix Scientific Group:

Bio-Matrix Scientific Group Inc. (OTC.BB:BMSN ) is the majority owner of Entest BioMedical Inc. BMSN is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.

Forward-looking statements:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Source: Bio-Matrix Scientific Group

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.